Strides Shasun receives USFDA Approval for Cyproheptadine Hydrochloride Tablets

Strides Shasun Limited today announced that its wholly owned subsidiary Strides Pharma Global Pte. Ltd. has received approval for Cyproheptadine Hydrochloride Tablets USP, 4 mg from the United States Food & Drug Administration (US FDA). Cyproheptadine Hydrochloride Tablets is a generic version of Periactin Tablets of Merck & Co. Inc.

According to IQVIA data, the US market for Cyproheptadine Hydrochloride Tablets USP, 4 mg is approximately USD 20 Million. The product will be manufactured at the company's Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market.

The company has 74 cumulative ANDA filings with USFDA of which 46 ANDAs have been approved as of date and 28 are pending approval.

Cyproheptadine Hydrochloride Tablets is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, sneezing, hives, and itching.

Shares of Strides Shasun Ltd was last trading in BSE at Rs.650.25 as compared to the previous close of Rs. 653.3. The total number of shares traded during the day was 18876 in over 603 trades.

The stock hit an intraday high of Rs. 658.6 and intraday low of 649.5. The net turnover during the day was Rs. 12320812.

Source : Equity Bulls

Keywords